News
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH issued an update on Formycon AG, maintaining a Buy recommendation and reducing the target price to €50. Recent positive developments drive optimism for Formycon's sales of Keytruda biosimilar FYB206 -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon Reports Positive Operational Progress and Strong Revenue Growth in the First Quarter of 2026
Formycon reports positive operational progress and strong revenue growth in the first quarter of 2026. Achievements in biosimilar portfolio and strategic roadmap. Financial figures and guidance confirmed -